Literature DB >> 19012863

Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials.

Donald J Connor1, Marwan N Sabbagh, Jeffery L Cummings.   

Abstract

BACKGROUND: The Neuropsychiatric Inventory (NPI) is commonly used in dementia trials to quantify and qualitate changes in psychiatric symptoms.
METHODS: A questionnaire was administered to clinical trial raters to assess whether they were being trained to administer and score the NPI differently between clinical trial protocols.
RESULTS: Responses to the survey indicated that there are differences between clinical trials protocols in how the instrument is administered and scored. DISCUSSION: Clarification of administration and scoring rules are provided, including the behavioral sampling period, whether premorbid characteristics are considered, and what behaviors are considered in rating frequency, severity, and caregiver distress.

Entities:  

Mesh:

Year:  2008        PMID: 19012863      PMCID: PMC2645415          DOI: 10.1016/j.jalz.2008.09.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  7 in total

1.  [Risperidone in the treatment of psychotic, affective and behavioral symptoms associated to Alzheimer's disease].

Authors:  D Barcia; E Giles; M Herraiz; A Moríñigo; M Roca; A Rodríguez
Journal:  Actas Esp Psiquiatr       Date:  1999 May-Jun       Impact factor: 1.196

2.  Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.

Authors:  Richard Mahlberg; Sebastian Walther; Uta Eichmann; Ferenc Tracik; Dieter Kunz
Journal:  Arch Gerontol Geriatr       Date:  2006-09-11       Impact factor: 3.250

3.  Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale.

Authors:  D I Kaufer; J L Cummings; D Christine; T Bray; S Castellon; D Masterman; A MacMillan; P Ketchel; S T DeKosky
Journal:  J Am Geriatr Soc       Date:  1998-02       Impact factor: 5.562

Review 4.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

5.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

6.  Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.

Authors:  D Kaufer
Journal:  Dement Geriatr Cogn Disord       Date:  1998       Impact factor: 2.959

7.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

  7 in total
  17 in total

1.  Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.

Authors:  Jun Ku Chung; Eric Plitman; Shinichiro Nakajima; M Mallar Chakravarty; Fernando Caravaggio; Philip Gerretsen; Yusuke Iwata; Ariel Graff-Guerrero
Journal:  J Geriatr Psychiatry Neurol       Date:  2015-09-23       Impact factor: 2.680

2.  Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

Authors:  Philippe Robert; Steven Ferris; Serge Gauthier; Ralf Ihl; Bengt Winblad; Frank Tennigkeit
Journal:  Alzheimers Res Ther       Date:  2010-08-26       Impact factor: 6.982

3.  Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

Authors:  J Cummings; P Aisen; R Barton; J Bork; R Doody; J Dwyer; J C Egan; H Feldman; D Lappin; L Truyen; S Salloway; R Sperling; G Vradenburg
Journal:  J Prev Alzheimers Dis       Date:  2016-03-04

4.  Gender role in sleep disturbances among older adults with traumatic brain injury.

Authors:  Conor Ledger; Wael K Karameh; David G Munoz; Corinne E Fischer; Tom A Schweizer
Journal:  Int Rev Psychiatry       Date:  2019-09-23

5.  Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias.

Authors:  Taim Muayqil; Richard Camicioli
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-11-23

6.  Globalization of Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Robert Reynders; Kate Zhong
Journal:  Alzheimers Res Ther       Date:  2011-08-17       Impact factor: 6.982

7.  Helicobacter pylori infection, dementia and primary open-angle glaucoma: are they connected?

Authors:  Fani Tsolaki; Jannis Kountouras; Fotios Topouzis; Magda Tsolaki
Journal:  BMC Ophthalmol       Date:  2015-03-11       Impact factor: 2.209

8.  Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders.

Authors:  Renaud David; Emmanuel Mulin; Patrick Mallea; Philippe H Robert
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-26

Review 9.  The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders.

Authors:  Claudia K Y Lai
Journal:  Clin Interv Aging       Date:  2014-07-08       Impact factor: 4.458

10.  Brazilian caregiver version of the Apathy Scale.

Authors:  Henrique Cerqueira Guimarães; Patricia Paes Araujo Fialho; Viviane Amaral Carvalho; Etelvina Lucas Dos Santos; Paulo Caramelli
Journal:  Dement Neuropsychol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.